San Antonio Breast Cancer Symposium 2019

Masakazu Toi (Kyoto University Hospital, Kyoto, Japan) presented the results of the randomised, phase 3 POTENT trial. 1959 patients with hormone receptor-positive, HER2-negative, stage I–III primary breast cancer at intermediate or high risk of recurrence were randomly assigned (1:1) after surgery to standard adjuvant endocrine therapy alone (control) or with oral S-1 (80 mg, 100 mg, or 120 mg…

Read the full article here

Related Articles

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial

The demonstrated delays in definitive deterioration in GHS/QoL, urinary symptoms, and other functioning and symptom scales with talazoparib plus enzalutamide compared with placebo plus enzalutamide…